(Total Views: 398)
Posted On: 06/09/2021 8:22:27 AM
Post# of 122
BIOGEN SCORES A BIG WIN FOR ADUHELM™, BUT THE PATH AHEAD ISN’T EASY!
A truly defining moment for Biogen which announced the approval of ADUHELM, intended for the treatment of Alzheimer’s disease, which specifically addresses the underlying cause of the disease, by removing amyloid beta from the brains of those afflicted with the condition.
However, the path ahead is not going to be easy with questions being raised about its efficacy and cost. Only time will tell if the drug manages to deliver on its promise for millions afflicted with the disease but for now the Company better buckle up for the challenges ahead!.
Insert-tag-herehttps://www.aviseanalytics.com/biogen-scores-a-big-win-for-aduhelm-but-the-path-ahead-isnt-easy/
A truly defining moment for Biogen which announced the approval of ADUHELM, intended for the treatment of Alzheimer’s disease, which specifically addresses the underlying cause of the disease, by removing amyloid beta from the brains of those afflicted with the condition.
However, the path ahead is not going to be easy with questions being raised about its efficacy and cost. Only time will tell if the drug manages to deliver on its promise for millions afflicted with the disease but for now the Company better buckle up for the challenges ahead!.
Insert-tag-herehttps://www.aviseanalytics.com/biogen-scores-a-big-win-for-aduhelm-but-the-path-ahead-isnt-easy/
(0)
(0)
